Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DVRd followed by ciltacabtagene autoleucel versus DVRd followed by autologous stem cell transplant in transplant-eligible newly diagnosed multiple myeloma
2021-003284-10Phase 3Active
- Sponsor
- Stichting European Myeloma Network (EMN)
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ciltacabtagene autoleucel, daratumumab, bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Stichting European Myeloma Network (EMN). Primary endpoint: Progression-free survival. Started Jul 2022; status: active.
02
Drugs
ciltacabtagene autoleuceldaratumumabbortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2021-003284-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003284-10.